CD274 and neoplasm: Our previous work [20] found that PD-L1 content was significantly increased in late relapsing TMZ-treated tumours compared to vehicle-treated tumours, which reveals that the upregulated expression of PD-L1 on tumour cells could be a potential link between chemotherapy and tumour immune resistance.